
<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Medical Device Regulatory Portfolio</title>
  <link rel="stylesheet" href="styles.css">
  <script src="https://kit.fontawesome.com/a076d05399.js" crossorigin="anonymous"></script>
 
</head>
<body>
  <nav class="navbar">
    <ul>
      <li><button onclick="showSection('intro')" class="active"><i class="fas fa-info-circle"></i> Introduction</button></li>
      <li><button onclick="showSection('aim-objective')"><i class="fas fa-bullseye"></i> Aim & Objective</button></li>
      <li><button onclick="showSection('theory')"><i class="fas fa-book"></i> Theory</button></li>
      <li><button onclick="showSection('result')"><i class="fas fa-chart-bar"></i> Result</button></li>
      <li><button onclick="showSection('discussion')"><i class="fas fa-comments"></i> Discussion</button></li>
      <li><button onclick="showSection('conclusion')"><i class="fas fa-check-circle"></i> Conclusion</button></li>
      <li><button onclick="showSection('references')"><i class="fas fa-book-open"></i> References</button></li>
    </ul>
  </nav>

  <header>
    <h1>Comparative Regulatory Strategy Portfolio</h1>
    <p>Implantable Pacemaker | Regulatory Pathways: FDA (USA), EU MDR (Europe), CDSCO (India)</p>
  </header>

  <main>
    <section id="intro" class="active">
      <h2>Introduction</h2>
      <div id="intro-content">
        <div class="text">
          <p>The implantable pacemaker is a life-sustaining Class III medical device used to manage cardiac arrhythmias. This portfolio offers an in-depth comparative regulatory study to evaluate how such a high-risk medical device is governed across three major global jurisdictions: the FDA (United States), the European Medical Device Regulation (MDR), and the Central Drugs Standard Control Organization (CDSCO, India).</p>
          <p>This study encapsulates device classification rationale, documentation requirements, technical file preparation, conformity assessments, post-market surveillance, and unique regional compliance mandates.</p>
          <img src="pacemaker.jpeg" alt="Implantable Pacemaker Diagram" class="diagram">
        </div>
        <div class="animation">
            <div style="text-align: center;">
                <img src="hello.gif" alt="Full GIF" style="max-width: 500px; height: auto;">
              </div>
              
        </div>
      </div>
      
  
     
  </section>


    <section id="aim-objective">
      <h2>Aim & Objective</h2>
      <p><strong>Aim:</strong> To develop a robust understanding of global regulatory strategies and compliance obligations for the lifecycle management of an implantable pacemaker.</p>
      <p><strong>Objectives:</strong></p>
      <ul>
        <li>Identify the governing regulatory bodies and device classification systems in the USA, Europe, and India.</li>
        <li>Compare the design and development controls including Design History File (DHF), Device Master Record (DMR), and Risk Management documentation.</li>
        <li>Analyze the regulatory pathways including Premarket Approval (PMA), CE Marking procedures, and Form MD-14/15 requirements.</li>
        <li>Evaluate safety and performance evaluation processes including biocompatibility, electrical safety, and clinical evaluation.</li>
        <li>Review post-market surveillance activities including vigilance reporting, periodic safety update reports (PSUR), and recalls.</li>
      </ul>
    </section>

    <section id="theory">
      <h2>Theory</h2>
      <p>A Class III implantable pacemaker comprises electrical circuitry and a power source enclosed in a biocompatible casing, designed to regulate cardiac rhythm via pulse generation. Due to the invasive and life-critical nature of the device, global regulations mandate extensive clinical evaluation, technical file documentation, and rigorous testing.</p>
      <p><strong>Regulatory Classifications:</strong></p>
      <ul>
        <li><strong>FDA (USA):</strong> Class III, requiring a Premarket Approval (PMA) submission.</li>
        <li><strong>EU MDR:</strong> Class III under Rule 20, requiring a CE Mark via a notified body with a full Quality Management System audit.</li>
        <li><strong>CDSCO (India):</strong> Class D, the highest risk class, requiring licensing under Form MD-14 and MD-15.</li>
      </ul>
      <p>The core evaluation framework includes risk-benefit analysis, ISO 13485 QMS conformance, clinical trials (if applicable), and adherence to IEC 60601 and ISO 14708 standards.</p>
    </section>

    <section id="result">
      <h2>Result</h2>
      <p>The following diagram visually represents the similarities and divergences across the regulatory frameworks. It covers core steps such as classification, conformity assessment, submission pathways, clinical evaluation needs, and post-market activities.</p>
      <img src="comparative diagram.png" alt="Regulatory Comparison Result" class="diagram">
    </section>

    <section id="discussion">
      <h2>Discussion</h2>
      <p>From the results, it's evident that while all three frameworks aim to ensure safety and efficacy, the depth of documentation, approval timelines, and clinical data requirements vary. For instance:</p>
      <ul>
        <li>The FDA PMA process demands extensive clinical investigation and may take several months to years.</li>
        <li>EU MDR mandates a strong focus on clinical evaluation reports and continuous PMS through PSURs and PMCF plans.</li>
        <li>CDSCO has been strengthening its processes with reference to global standards but still exhibits procedural variances and dependencies on international certifications.</li>
      </ul>
      <p>Harmonization efforts such as the IMDRF and reliance on ISO standards are helping reduce redundancy in submissions and support global market entry for manufacturers.</p>
    </section>

    <section id="conclusion">
      <h2>Conclusion</h2>
      <p>In conclusion, developing an implantable pacemaker for global markets demands comprehensive knowledge of regional regulatory expectations. This portfolio demonstrates the strategic planning required to meet jurisdiction-specific requirements while aligning with international quality and safety standards. Regulatory convergence and digital health technologies are shaping future paradigms, enabling streamlined submissions, real-world evidence integration, and enhanced post-market surveillance capabilities.</p>
    </section>

    <section id="references">
      <h2>References</h2>
      <ul>
        <li>U.S. Food and Drug Administration (FDA) – Premarket Approval (PMA) Guidance</li>
        <li>European Commission – Medical Device Regulation (EU MDR 2017/745)</li>
        <li>Central Drugs Standard Control Organization (CDSCO) – Medical Device Rules (2017)</li>
        <li>ISO 13485:2016 – Medical devices – Quality management systems</li>
        <li>IEC 60601 – Medical Electrical Equipment Standard</li>
        <li>ISO 14708 – Implants for surgery — Active implantable medical devices</li>
        <li>International Medical Device Regulators Forum (IMDRF) publications</li>
      </ul>
    </section>
  </main>

  <footer>
    &copy; 2025 Abhishek Kumar Jha | Biomedical Engineering Portfolio
  </footer>
<script src="script.js"></script>
  
</body>
</html>